Key Client Fiduciary Advisors’s AbbVie ABBV Stock Holding History

Key Client Fiduciary Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.49M	Buy	5,928 +72	+1%	+$15.5K	0.43%	49
2026 Q1	$1.27M	Sell	5,856 -158	-3%	-$35K	0.43%	54
2025 Q4	$1.37M	Sell	6,014 -7,568	-56%	-$1.72M	0.47%	52
2025 Q3	$3.14M	Sell	13,582 -1	-0%	-$204	1.04%	17
2025 Q2	$2.52M	Buy	13,583 +10	+0.1%	+$1.86K	1.02%	21
2025 Q1	$2.84M	Sell	13,573 -79	-0.6%	-$15.4K	1.29%	16
2024 Q4	$2.43M	Buy	13,652 +14	+0.1%	+$2.57K	1.07%	18
2024 Q3	$2.69M	Sell	13,638 -94	-0.7%	-$17.5K	1.21%	15
2024 Q2	$2.36M	Sell	13,732 -756	-5%	-$125K	1.17%	16
2024 Q1	$2.64M	Sell	14,488 -863	-6%	-$149K	1.4%	15
2023 Q4	$2.38M	Sell	15,351 -1,164	-7%	-$170K	1.38%	16
2023 Q3	$2.46M	Buy	16,515 +77	+0.5%	+$11.3K	1.51%	18
2023 Q2	$2.21M	Sell	16,438 -184	-1%	-$27K	1.29%	18
2023 Q1	$2.65M	Buy	16,622 +198	+1%	+$30.3K	1.65%	15
2022 Q4	$2.65M	Buy	16,424 +13,719	+507%	+$2.1M	1.79%	12
2022 Q3	$363K	Buy	2,705 +22	+0.8%	+$3.16K	0.33%	67
2022 Q2	$411K	Sell	2,683 -60	-2%	-$9.17K	0.4%	61
2022 Q1	$445K	Sell	2,743 -13	-0.5%	-$1.89K	0.35%	67
2021 Q4	$373K	Buy	+2,756	New	+$326K	0.31%	81

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Key Client Fiduciary Advisors's ABBV Position: Q2 2026 in Review

Key Client Fiduciary Advisors increased its AbbVie (ABBV) stake by 1.2% in Q2 2026, buying an estimated $15.5K and bringing the position to 5,928 shares worth $1.49M. The position accounts for 0.43% of the portfolio, ranked #49.

Key Client Fiduciary Advisors first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. The position peaked at $3.14M in Q3 2025. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Key Client Fiduciary Advisors held 5,928 shares of AbbVie worth $1.49M as of Q2 2026.
Key Client Fiduciary Advisors bought 72 AbbVie shares in Q2 2026, an estimated $15.5K.
AbbVie made up 0.43% of Key Client Fiduciary Advisors's portfolio in Q2 2026, its #49 holding.
Key Client Fiduciary Advisors first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
Key Client Fiduciary Advisors's AbbVie position peaked at $3.14M in Q3 2025.
4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Key Client Fiduciary Advisors's 13F filing for Q2 2026, filed 9 Jul 2026.